HPV nine-valent vaccine expands to 9-45 years old

On August 30, the new indication of the nine-valent papilloma virus vaccine (brewing yeast) (hereinafter referred to as "nine-valent HPV vaccine") was approved by the State Drug Administration. Age is 16-26 years old.

The reporter learned that the nine -valent HPV vaccine uses a three -dose immune program and is suitable for cervical cancer caused by HPV 16, 18, 31, 33, 45, 52, and 58; Cervical epithelial tumor -like lesions (CIN1/2/3) caused by type 45, 52 and 58 and cervical adenocarcinoma (AIS); and HPV 6, 11, 16, 18, 31, 45, 52, and Continuous infection caused by type 58.

Cervical cancer is one of the common gynecological malignant tumors. In 2021, ICO/IARC's HPV and related diseases in China show that in 2020, among women 15-44 years old in China, the incidence and mortality rate of cervical cancer ranks third in female tumors. In China, about 98%of cervical cancer is caused by high -risk HPV. Although HPV16 and 18 are high -risk HPVs that are widely popular worldwide, there are differences in epidemiological research in China. Type HPVs are HPV 16, 52, and 58.

The reporter learned that Meridon has currently carried out clinical research on a number of new indications of HPV vaccines in China at the same time, hoping to help more people benefit in the future. Enterprises will continue to work closely with the government, society, business partners and parties to the society. By expanding the global production capacity and increasing the supply of the Chinese market, it will continuously improve the accessibility of the HPV vaccine.

The reporter learned from the Nanjing Centers for Disease Control and Prevention Center and many community health service centers that the units have not yet received a notice of the age limit of the nine -valent HPV vaccine. Nine -valent vaccine newly applies age, and "over -aged" women who want to vaccinate the nine -valent vaccine should not run short for the time being. Yangtze Evening News/Zi Niu Journalist Yang Yan

Edit: Qin Xiaoyi

- END -